Results & Financial lifeHealthcare - Pharma - Biotech
GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12
03/11/2026 08:05
AMFImmediate publication
Berlin, Germany, November 3, 2026, 08.00 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, announces that the clinical and translational team of the GLORIA study1 have received the Award of German University Medicine…
GLORIA Study Team Receives the 2026 German University Medicine Prize for
Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12
- Researchers from six German university medical centers have received the 2026 German University Medicine Prize for their work in the GLORIA study
- GLORIA, TME Pharma’s Phase 1/2 study, evaluates NOX-A12 in combination with radiotherapy in newly diagnosed glioblastoma patients who are resistant to chemotherapy. In an expansion cohort, NOX-A12 and radiotherapy were also combined with bevacizumab
- The prize jury was impressed by the successful combination of basic research and clinical application and the outstanding cross-site, interdisciplinary teamwork
- TME Pharma welcomes this independent external validation of its therapeutic approach in glioblastoma by the German medical community
- This announcement comes as TME Pharma has reached an exclusive negotiation agreement with TMS Co., Ltd. on worldwide rights to NOX-A12
Berlin, Germany, November 3, 2026, 08.00 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, announces that the clinical and translational team of the GLORIA study1 have received the Award of German University Medicine 2026. It is awarded to one team each year by the German Association of Medical Faculties (MFT) and the Association of German University Hospitals (VUD), which announced the award on
October 22, 2026.2
Background of the Prize
The German University Medicine Prize recognizes outstanding team achievements in university medical research, in particular innovation, the translation of research results into patient care, and their societal relevance. MFT and VUD represent the 40 medical faculties and 37 university hospita ls in Germany.
The awarded GLORIA trial team comprises specialists in radiation oncology, neuro-oncology, neurosurgery, neuroradiology and neuropathology at the university medical centers of Bonn, Essen, Leipzig, Mannheim, Münster and Tübingen. Clinical leadership of the study lies with Dr. Frank Giordano (Mannheim); translational leadership lies with Dr. Julian Layer (Bonn). The prize ceremony will take place on November 24, 2026 in Berlin.
Scientific Rationale and Results Cited by the Awarding Bodies
A key mechanism of glioblastoma recurrence is the rapid re-establishment of the tumor’s blood supply after irradiation. Tumors use chemokines such as CXCL12 to rebuild their blood supply and to evade immune attack. NOX-A12 is designed to neutralize CXCL12.
1 NCT04121455 - GLORIA study on clinicaltrials.gov